Stay updated with breaking news from Accelerating Discovery. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints) study will follow 200 patients with cirrhosis – scarring caused by long-term damage of the liver – to uncover why some patients experience liver failure or develop liver cancer
The FINANCIAL -- The ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints) study will follow 200 patients with cirrhosis – scarring caused by long-term damage of the liver – to uncover why some patients experience liver failure or develop liver cancer. Researchers from the Universities of Edinburgh and Newcastle hope their findings will lead to earlierThe FINANCIAL -- The ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis Endpoints) study will follow 200 patients with cirrhosis – scarring caused by long-term damage of the liver – to uncover why some patients exp...
The most extensive clinical study into liver cirrhosis ever conducted worldwide has been announced by Newcastle University, University of Edinburgh and leading research-driven global biopharmaceutical company, Boehringer Ingelheim.
Newcastle and Edinburgh Universities have announced the launch of the most extensive clinical study into liver cirrhosis conducted worldwide.
Looking for the latest Government Contracting News? Check out our story: DARPA Aims to Develop Novel Tunable Optical Materials for Fast-Switching